Skip to main content

NOVISTIG (Boucher & Muir Pty Ltd)

Product name
NOVISTIG
Date registered
Evaluation commenced
Decision date
Approval time
228 working days (255)
Active ingredients
neostigmine methylsulfate; glycopyrronium bromide (glycopyrrolate)
Registration type
NCE/NBE
Indication

NOVISTIG (solution for injection) is indicated for reversal of residual non-depolarising (competitive) neuromuscular block.

Help us improve the Therapeutic Goods Administration site